SCHEMBL19862542

SCHEMBL19862542

CC(C)Cc1ccc(-c2ccc(Cl)cn2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 1/20 0.42
SLC6A3 Q01959 1/20 0.42
XDH P47989 1/20 0.41
ACACB O00763 1/20 0.41
GRIA2 P42262 1/20 0.40
CNR2 P34972 1/20 0.40
GRM2 Q14416 1/20 0.40
CYP3A4 P08684 1/20 0.40
PTPN1 P18031 1/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
NFKB1 P19838 1/20 0.39
MAPK1 P28482 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
KDM1A O60341 1/20 0.39
MAOB P27338 1/20 0.39
DHODH Q02127 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL765757 0.81 CCR1 (0.50) XDHGRIA2CYP3A4PTPN1NPC1
SCHEMBL10332074 0.81 RAB9A (0.58) XDHPTPN1NPC1RAB9ASMN1; SMN2
SCHEMBL19865619 0.81 RAB9A (0.53) CNR2GRM2CYP3A4NPC1RAB9A
SCHEMBL22275581 0.80 XDH (0.41) XDHPTPN1NPC1RAB9ASMN1; SMN2
SCHEMBL18573123 0.80 XDH (0.48) XDHPTPN1NPC1RAB9ASMN1; SMN2
SCHEMBL19398968 0.80 BRS3 (0.48) XDHGRIA2PTPN1NPC1RAB9A
SCHEMBL21035108 0.79 CNR2 (0.44) CNR2GRM2CYP3A4NPC1RAB9A
SCHEMBL21342286 0.79 CYP11B1 (0.47) CYP3A4NPC1RAB9ASMN1; SMN2DHODH
SCHEMBL13017139 0.79 KDM1A (0.43) XDHGRM2CYP3A4NPC1RAB9A
SCHEMBL18790914 0.79 CYP11B1 (0.47) CYP3A4NPC1RAB9ASMN1; SMN2DHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180044343-A1 BICYCLIC IMIDAZOLO DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2018-02-15 US disclosed
US-20180044343-A1 BICYCLIC IMIDAZOLO DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2018-02-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180044343-A1 BICYCLIC IMIDAZOLO DERIVATIVE PDE3A, PDE2A, PDE5A SLC6A2 4252/4885SLC6A3 3060/4885XDH 147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.